510 related articles for article (PubMed ID: 23748506)
1. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
Grimm M; Han J; Weaver C; Griffin P; Schulteis CT; Dong H; Malloy J
Postgrad Med; 2013 May; 125(3):47-57. PubMed ID: 23748506
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
Malloy J; Meloni A; Han J
Postgrad Med; 2013 May; 125(3):58-67. PubMed ID: 23748507
[TBL] [Abstract][Full Text] [Related]
3. Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.
Wysham CH; MacConell LA; Maggs DG; Zhou M; Griffin PS; Trautmann ME
Mayo Clin Proc; 2015 Mar; 90(3):356-65. PubMed ID: 25744115
[TBL] [Abstract][Full Text] [Related]
4. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
[TBL] [Abstract][Full Text] [Related]
5. Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications.
Pencek R; Brunell SC; Li Y; Hoogwerf BJ; Malone J
Postgrad Med; 2012 Jul; 124(4):33-40. PubMed ID: 22913892
[TBL] [Abstract][Full Text] [Related]
6. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas.
Davies M; Heller S; Sreenan S; Sapin H; Adetunji O; Tahbaz A; Vora J
Diabetes Care; 2013 May; 36(5):1368-76. PubMed ID: 23275363
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
[TBL] [Abstract][Full Text] [Related]
8. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.
Grimm M; Li Y; Brunell SC; Blase E
Postgrad Med; 2013 Sep; 125(5):101-8. PubMed ID: 24113668
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study.
Henry RR; Klein EJ; Han J; Iqbal N
Diabetes Technol Ther; 2016 Nov; 18(11):677-686. PubMed ID: 27525540
[TBL] [Abstract][Full Text] [Related]
10. Once-weekly exenatide as a treatment for Type 2 diabetes.
Schauerhamer MB; Gurgle H; McAdam-Marx C
Expert Rev Cardiovasc Ther; 2015 Jun; 13(6):611-26. PubMed ID: 26000560
[TBL] [Abstract][Full Text] [Related]
11. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.
Bergenstal RM; Li Y; Porter TK; Weaver C; Han J
Diabetes Obes Metab; 2013 Mar; 15(3):264-71. PubMed ID: 23078638
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
Aroda VR; DeYoung MB
Postgrad Med; 2011 Sep; 123(5):228-38. PubMed ID: 21904106
[TBL] [Abstract][Full Text] [Related]
13. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.
Ridge T; Moretto T; MacConell L; Pencek R; Han J; Schulteis C; Porter L
Diabetes Obes Metab; 2012 Dec; 14(12):1097-103. PubMed ID: 22734440
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
[TBL] [Abstract][Full Text] [Related]
15. Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data.
Trautmann ME; Han J; Ruggles J
Clin Ther; 2016 Jun; 38(6):1464-1473. PubMed ID: 27126504
[TBL] [Abstract][Full Text] [Related]
16. Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations.
Pencek R; Blickensderfer A; Li Y; Brunell SC; Chen S
Int J Clin Pract; 2012 Nov; 66(11):1021-32. PubMed ID: 22925173
[TBL] [Abstract][Full Text] [Related]
17. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
Norwood P; Liutkus JF; Haber H; Pintilei E; Boardman MK; Trautmann ME
Clin Ther; 2012 Oct; 34(10):2082-90. PubMed ID: 23031623
[TBL] [Abstract][Full Text] [Related]
18. Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index.
Pencek R; Blickensderfer A; Li Y; Brunell SC; Anderson PW
Postgrad Med; 2012 Jul; 124(4):21-32. PubMed ID: 22913891
[TBL] [Abstract][Full Text] [Related]
19. Is insulin the most effective injectable antihyperglycaemic therapy?
Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
